|1.||McLennan, Gordon: 4 articles (06/2013 - 11/2005)|
|2.||Jayaram, H N: 4 articles (05/2004 - 02/2001)|
|3.||Bansal, Navin: 3 articles (06/2013 - 06/2011)|
|4.||Jayaram, Hiremagalur N: 3 articles (06/2013 - 04/2002)|
|5.||Szekeres, T: 3 articles (02/2002 - 02/2001)|
|6.||Babsky, Andriy: 2 articles (06/2013 - 06/2012)|
|7.||Bonnac, Laurent: 2 articles (06/2013 - 06/2012)|
|8.||Bennett, Stacy L: 2 articles (06/2013 - 06/2012)|
|9.||Ju, Shenghong: 2 articles (06/2012 - 06/2011)|
|10.||Novotny, Ladislav: 2 articles (04/2002 - 04/2002)|
06/01/2012 - "Benzamide riboside (BR) induces tumor apoptosis in multiple cell lines and animals. "
04/01/2002 - "Benzamide riboside (BR), a synthetic C-nucleoside, acts as a strong growth inhibitor of cancer cells in vitro and in vivo. "
04/01/2002 - "Inhibition of the enzyme by benzamide riboside selectively inhibits tumor cell growth and induces apoptosis in various human tumor cell lines. "
10/12/2001 - "Benzamide riboside (BR) is a novel anticancer agent exhibiting pronounced activity against several human tumor cells, however, little is known about its biotransformation. "
03/15/1994 - "On kinetic grounds, it was deduced that benzamide riboside (whose Ki versus IMPDH is 6.4 mM, while that of its 5'-monophosphate is 3.9 mM) or its 5'-monophosphate were unlikely to be responsible for inhibition of this target enzyme, IMPDH, since only micromolar concentrations of benzamide riboside were needed to exert potent inhibition of tumor-cell growth. "
|2.||Hepatocellular Carcinoma (Hepatoma)
06/01/2013 - "This pilot trial assesses variability of apoptosis and response 1 day after hepatic intraarterial (IA) benzamide riboside (BR) in rodent hepatomas and its correlation to water apparent diffusion coefficient (ADC) and single-quantum (SQ) and triple-quantum-filtered (TQF) sodium-23 ((23)Na) magnetic resonance (MR) imaging. "
06/01/2011 - "Predicting response to benzamide riboside chemotherapy in hepatocellular carcinoma using apparent diffusion coefficient of water."
06/01/2012 - "Tumor response and apoptosis of N1-S1 rodent hepatomas in response to intra-arterial and intravenous benzamide riboside."
06/01/2011 - "To monitor the effects of the apoptotic agent benzamide riboside (BR) on tumor volume and water apparent diffusion coefficient (ADC) in rat hepatocellular carcinoma (HCC). "
06/01/2013 - "Variability of apoptosis and response in N1-S1 rodent hepatomas to benzamide riboside and correlation to early changes in water apparent diffusion coefficient and sodium MR imaging."
02/01/2001 - "Benzamide riboside (BR), a new synthetic nucleoside analogue, has demonstrated a potent cytotoxic activity in murine leukemia in vitro. "
04/01/2002 - "Benzamide riboside might be clinically used in the treatment of leukemia and solid tumors, alone or as part of combination therapy. "
04/01/2002 - "In this manuscript we describe the induction of the CD71 transferrin receptor in human promyelocytic leukemia HL-60 cells following treatment with benzamide riboside. "
01/01/1998 - "Staurosporine enhanced benzamide riboside-induced apoptosis in human multidrug-resistant promyelocytic leukemia cells (HL-60/VCR) in vitro."
01/01/1998 - "The inosine monophosphate (IMP) dehydrogenase inhibitor benzamide riboside (BR) induced apoptosis (detected with the aid of flow cytometric identification of cells with sub-G0 DNA content and increased side angle light scatter) equally or slightly more intensively in the multidrug-resistant human promyelocytic leukemia cell line (HL-60/VCR: MDR-1 gene, Pgp positive) in comparison with the parental drug sensitive HL-60 cells. "
|4.||Myeloid Leukemia (Leukemia, Myelocytic)
08/14/1992 - "Cytotoxicity of a new IMP dehydrogenase inhibitor, benzamide riboside, to human myelogenous leukemia K562 cells."
03/15/1994 - "Incubation of human myelogenous leukemia K562 cells with an IC50 concentration of benzamide riboside resulted in an expansion of IMP pools (5.9-fold), with a parallel reduction in the concentration of GMP (90%), GDP (63%), GTP (55%) and dGTP (40%). "
01/01/2000 - "The differential sensitivity of examined human ovarian carcinoma cell lines (CH1, A-2780 and SKOV-3) to the IMPDH inhibitor, benzamide riboside (BR), was demonstrated with the aid of MTT assay. "
01/01/2000 - "Differential sensitivity of ovarian carcinoma cell lines to apoptosis induced by the IMPDH inhibitor benzamide riboside."
08/01/1999 - "Benzamide riboside induces apoptosis independent of Cdc25A expression in human ovarian carcinoma N.1 cells."
|2.||Inosine Monophosphate (IMP)
|3.||Benzoic Acid (Ucephan)
|5.||Transferrin (beta 2 Transferrin)
|7.||Transferrin Receptors (Transferrin Receptor)
|1.||Drug Therapy (Chemotherapy)